Cybin Inc. (HELP) – What Are Researchers Saying About This Stock?

Cybin Inc. (NASDAQ:HELP) has received an average rating of “Buy” from the six analysts that are covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $46.33.

A number of equities analysts have weighed in on the company. Wall Street Zen cut Cybin from a “sell” rating to a “strong sell” rating in a report on Saturday, October 3rd. Barclays assumed coverage on shares of Cybin in a research note on Friday, September 18th. They set an “overweight” rating and a $35.00 price objective on the stock. Wells Fargo & Company started coverage on shares of Cybin in a research note on Monday, July 27th. They issued an “overweight” rating and a $16.00 target price for the company. Finally, TD Cowen raised their price target on shares of Cybin from $8.00 to $62.00 and gave the company a “buy” rating in a report on Thursday, August 20th.

Cybin Price Performance

Shares of HELP opened at $11.80 on Friday. The stock’s 50-day moving average is $12.07 and its two-hundred day moving average is $7.78. The stock has a market cap of $939.16 million, a PE ratio of -3.91 and a beta of 0.53. Cybin has a 12 month low of $3.76 and a 12 month high of $15.15.

Cybin (NASDAQ:HELP) last posted its earnings results on Friday, August 14th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.11). On average, research analysts anticipate that Cybin will post -2.95 earnings per share for the current year.

Insider Activity

In other Cybin news, insider Paul Glavine bought 100,000 shares of the company’s stock in a transaction dated Tuesday, September 8th. The shares were acquired at an average cost of $12.47 per share, with a total value of $1,247,000.00. Following the completion of the transaction, the insider owned 4,271,252 shares in the company, valued at $53,262,512.44. The trade was a 2.40% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eric H. L. So purchased 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The stock was acquired at an average price of $12.39 per share, for a total transaction of $1,239,000.00. Following the purchase, the insider owned 4,465,014 shares of the company’s stock, valued at approximately $55,321,523.46. This represents a 2.29% increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders purchased 688,000 shares of company stock valued at $8,422,830. Corporate insiders own 15.00% of the company’s stock.

Institutional Investors Weigh In On Cybin

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Pale Fire Capital SE acquired a new position in shares of Cybin in the 2nd quarter valued at approximately $1,015,000. Farther Finance Advisors LLC boosted its stake in shares of Cybin by 927.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 22,818 shares of the company’s stock valued at $280,000 after buying an additional 20,597 shares during the last quarter. Finally, AXQ Capital LP acquired a new stake in shares of Cybin during the second quarter worth approximately $75,000. 17.94% of the stock is currently owned by hedge funds and other institutional investors.

About Cybin

Cybin Inc is a clinical-stage biotechnology company focused on developing psychedelic-based therapeutics for mental health conditions. The company combines psychedelic compounds with drug-delivery technologies and treatment protocols designed to improve the safety, consistency and duration of psychedelic-assisted therapies.

Cybin’s development programs have included CYB003, an investigational deuterated psilocybin therapy being studied for major depressive disorder, and CYB004, an investigational formulation of N,N-dimethyltryptamine (DMT) being evaluated for generalized anxiety disorder.